Skip to content

Physical Activity and Pacemaker Study

Reducing Sedentary Time in Individuals With Pacemakers - Tracking By Pacemaker-Based Accelerometry

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03052829
Enrollment
21
Registered
2017-02-14
Start date
2017-03-01
Completion date
2019-07-01
Last updated
2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arrythmia, Cardiovascular Diseases, Pacemaker, Physical Activity

Brief summary

The benefits of regular physical activity are well-established. Furthermore, the investigators have previously shown that in a population of patients with implanted pacemakers, those who exercise more than 2 hours daily have improved survival compared with those who exercise less than 2 hours daily. In this study, the aim f the investigators is to determine whether the offering subjects with pacemakers who have low levels of physical activity at baseline counseling to increase physical activity levels is effective as measured by their implanted device as well as by an external pacemaker. The investigators seek to enroll about 30 patients into a 6-month 1:1 randomized interventional trial comparing the levels of physical activity in 2 groups, those who receive physical activity counseling versus usual care. The activity levels will be measured with external pedometers and with accelerometers embedded within the pacemaker device.

Detailed description

The benefits of habitual physical activity (PA, activities of at least moderate intensity defined as ≥ 3 metabolic equivalents (METs)) are well-recognized. Emerging information from large data sets strongly suggest high levels of sedentary behavior, defined as activities \<1.5 METs (equivalent to the amount of energy expended during seated activities such as computer work) increases the risk of diabetes, cardiovascular disease, and death, independent of the amount and intensity PA. The increased risk of sedentary behavior appears to be mediated at least in part by reduced insulin sensitivity, impaired lipid metabolism, increased vascular inflammation, and increased thrombotic tendencies. The internal accelerometer embedded in Medtronic pacemakers registers, stores, and reports total number of active time based on a threshold activity intensity level of approximately 70 steps/min (estimated to be \> 1.5 METs). This implanted accelerometer, combined with the regular follow-up required for appropriate care make individuals who have undergone Medtronic pacemaker implantation an ideal population in which to evaluate the impact of altering sedentary behavior on mortality and cardiovascular events. The hypotheses are as follows: 1. a 12 week intervention to increase moderate intensity physical activity delivered at the point of care in patients with pacemakers will result in parallel increases in active time as measured by the pacemaker and step count as measured by pedometer. 2. the increase in activity measured by both the metrics in hypothesis 1 will be greater than with usual care. Potential subjects who are interested in the study will have a screening visit to determine whether they meet the inclusion and exclusion criteria. Those who qualify and agree to participate will be randomized into either the Physical Activity Counseling arm (intervention arm) or the Patient Usual Care arm (control arm). Subjects in the interventional arm will be given a pedometer and physical activity counseling on a regular basis for 3 months. Physical activity data from their external pedometer will be collected every 2 weeks via phone calls. Accelerometry data from the implanted pacemaker will be collected from the subject's medical record as pacemaker interrogations are performed every 3 months as part of routine clinical care. After the initial 3 month interventional phase is complete, these subjects will be followed for another 3 months with collection of pedometer as well as accelerometer data as described above. Subjects in the control arm will be given pedometers for the week prior to pacemaker interrogation. These subjects will be called to report the number of steps they walked each day prior to the interrogation. Their accelerometry data will be captured through routine clinical pacemaker interrogations. The primary outcome is the physical activity level in each group as measured by the accelerometer at time 0, 3 months and 6 months. The secondary outcome is the step count in each group as measured by the pedometer at the same time points.

Interventions

BEHAVIORALPhysical activity counseling

Subjects in this arm will receive counseling on how to increase their physical activity level.

BEHAVIORALUsual care

Subjects will undergo their usual care without intervention

Sponsors

Medtronic
CollaboratorINDUSTRY
University of Wisconsin, Milwaukee
CollaboratorOTHER
Medical College of Wisconsin
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
55 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \> 55 years old * Clinical indication for placement of permanent pacemaker * LVEF of ≥ 50% at the time of or within 72 hours of implantation. * Able to ambulate * Average active time of ≤ 2 hours/day based on Revo or EnRhythm Accelerometery read out for the 3 month period prior to enrollment * Able to take 650 steps over 10 minutes following pacemaker implantation (\ 2-2.5 mph walking speed)

Exclusion criteria

* Follow up for implantation planned at a non-study center at the time of implantation. * Individuals with and expected life span of 1 year or less at the time of implantation * Known history of cognitive impairment or inability to follow study procedures

Design outcomes

Primary

MeasureTime frameDescription
Physical Activity Level as Measured by Embedded Accelerometer6 monthsThis is the daily measured active hours in the device

Secondary

MeasureTime frameDescription
Physical Activity Level as Measured by External Pedometer6 monthsthis is a daily step count (one week average)

Countries

United States

Participant flow

Participants by arm

ArmCount
Physical Activity Counseling
Subjects will be given counseling on the benefits of increasing activity, instructions on how to slowly increase their activity over 12 weeks with walking, record their daily step counts, and have bi-weekly phone calls with study staff to reinforce the training and help them overcome barriers to being physically active. Physical activity counseling: Subjects in this arm will receive counseling on how to increase their physical activity level.
7
Patient Usual Care
Subjects will undergo usual care without intervention in this study arm Usual care: Subjects will undergo their usual care without intervention
6
Total13

Baseline characteristics

CharacteristicPhysical Activity CounselingTotalPatient Usual Care
ACEI or ARB Therapy3 Participants7 Participants4 Participants
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
7 Participants13 Participants6 Participants
Age, Categorical
Between 18 and 65 years
0 Participants0 Participants0 Participants
Age, Continuous84 years
STANDARD_DEVIATION 5
80 years
STANDARD_DEVIATION 6
75 years
STANDARD_DEVIATION 5
Atrial Fibrillation3 Participants7 Participants4 Participants
Beta Blocker Therapy4 Participants7 Participants3 Participants
Body Mass Index30.0 kg/m2
STANDARD_DEVIATION 5
31.2 kg/m2
STANDARD_DEVIATION 5.7
32.5 kg/m2
STANDARD_DEVIATION 6.6
Calculated Gait Speed0.84 m/sec
STANDARD_DEVIATION 0.14
0.85 m/sec
STANDARD_DEVIATION 0.16
0.86 m/sec
STANDARD_DEVIATION 0.18
Coronary Stent1 Participants1 Participants0 Participants
Creatinine Clearance < 60 mL/min/1.73 m24 Participants5 Participants1 Participants
Current Smoker0 Participants1 Participants1 Participants
DBP70 mmHg
STANDARD_DEVIATION 9
73 mmHg
STANDARD_DEVIATION 14
77 mmHg
STANDARD_DEVIATION 18
Diabetes0 Participants3 Participants3 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
7 Participants13 Participants6 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Heart Failure0 Participants2 Participants2 Participants
High Degree AV Block6 Participants9 Participants3 Participants
History of Non-Sustained Ventricular Tachycardia2 Participants7 Participants5 Participants
History of Sustained Ventricular Tachycardia0 Participants3 Participants3 Participants
HMG CoA Reductase Therapy4 Participants8 Participants4 Participants
HR66 bpm
STANDARD_DEVIATION 4
68 bpm
STANDARD_DEVIATION 6
70 bpm
STANDARD_DEVIATION 7
Hyperlipidemia6 Participants12 Participants6 Participants
Hypertension6 Participants10 Participants4 Participants
LVEF%62 %
STANDARD_DEVIATION 3
60 %
STANDARD_DEVIATION 4
57 %
STANDARD_DEVIATION 4
LV End Diastolic Dimension43 mm
STANDARD_DEVIATION 3
44 mm
STANDARD_DEVIATION 5
44 mm
STANDARD_DEVIATION 6
LV End Systolic Dimension26 mm
STANDARD_DEVIATION 2
28 mm
STANDARD_DEVIATION 6
30 mm
STANDARD_DEVIATION 9
Moderate or Greater Mitral Regurgitation2 Participants2 Participants0 Participants
Pacemaker detected active minutes1.59 hours/day
STANDARD_DEVIATION 0.44
1.60 hours/day
STANDARD_DEVIATION 0.33
1.62 hours/day
STANDARD_DEVIATION 0.18
Pedometer-Based Daily Step Count2827 steps/day
STANDARD_DEVIATION 1641
2618 steps/day
STANDARD_DEVIATION 1594
2474 steps/day
STANDARD_DEVIATION 1623
Percent Atrial Pacing66 %
STANDARD_DEVIATION 31
61 %
STANDARD_DEVIATION 34
53 %
STANDARD_DEVIATION 38
Percent Ventricular Pacing12 %
STANDARD_DEVIATION 21
22 %
STANDARD_DEVIATION 38
34 %
STANDARD_DEVIATION 51
Prior CABG1 Participants1 Participants0 Participants
Prior CVA1 Participants5 Participants4 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
1 Participants2 Participants1 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
6 Participants11 Participants5 Participants
Region of Enrollment
United States
7 participants13 participants6 participants
SBP131 mmHg
STANDARD_DEVIATION 27
126 mmHg
STANDARD_DEVIATION 22
121 mmHg
STANDARD_DEVIATION 14
Sex: Female, Male
Female
6 Participants11 Participants5 Participants
Sex: Female, Male
Male
1 Participants2 Participants1 Participants
Sick Sinus Syndrome1 Participants4 Participants3 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 70 / 6
other
Total, other adverse events
0 / 70 / 6
serious
Total, serious adverse events
0 / 70 / 6

Outcome results

Primary

Physical Activity Level as Measured by Embedded Accelerometer

This is the daily measured active hours in the device

Time frame: 6 months

ArmMeasureValue (MEAN)Dispersion
Physical Activity CounselingPhysical Activity Level as Measured by Embedded Accelerometer1.97 active hours/dayStandard Deviation 0.56
Patient Usual CarePhysical Activity Level as Measured by Embedded Accelerometer1.77 active hours/dayStandard Deviation 0.22
Secondary

Physical Activity Level as Measured by External Pedometer

this is a daily step count (one week average)

Time frame: 6 months

ArmMeasureValue (MEAN)Dispersion
Physical Activity CounselingPhysical Activity Level as Measured by External Pedometer1769 steps/dayStandard Deviation 771
Patient Usual CarePhysical Activity Level as Measured by External Pedometer2487 steps/dayStandard Deviation 1800

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026